Catalog No.
DHD12602
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15692
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
12-IgG1, F(ab)-12 IgG1, Fab-12 IgG1, rhuMAb-VEGF, ABP 215, CAS: 216974-75-3
Clone ID
Bevacizumab
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook, PMID: 32335505
Bevacizumab-induced hypertension: Clinical presentation and molecular understanding, PMID: 28882537
The role of bevacizumab in the treatment of glioblastoma, PMID: 28527008
Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars, PMID: 28801849
Bevacizumab in advanced lung cancer: state of the art, PMID: 28812378
Bevacizumab in ovarian cancer: A critical review of phase III studies, PMID: 27852039
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial, PMID: 28481967
Bevacizumab in Cervical Cancer: 5 Years After, PMID: 30119082
The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review, PMID: 29710531
[Bevacizumab], PMID: 30634827
Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity, PMID: 29223789
Bevacizumab treatment of meningeal melanoma metastases, PMID: 31915016
The use of bevacizumab in pediatric retinal and choroidal disease: A review, PMID: 30757919
Introduction by the Guest Editors: Bevacizumab, PMID: 30119078
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma, PMID: 32564774
[Progress of Bevacizumab in the Front-line Treatment of Advanced Non-small Cell Lung Cancer], PMID: 32702797
Commentary: Single-use bevacizumab: The final solution?, PMID: 32461440
Systemic bevacizumab for recurrent respiratory papillomatosis, PMID: 32906078
Perforating folliculitis triggered by bevacizumab administration, PMID: 32463526
Vascular effect of bevacizumab: is it too early to draw conclusions?, PMID: 31913945
Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature, PMID: 29580267
Critical appraisal of bevacizumab in the treatment of ovarian cancer, PMID: 25960638
Monitoring antiangiogenesis of bevacizumab in zebrafish, PMID: 30122900
Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer, PMID: 32272489
Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer, PMID: 30663563
Off-label infusion of biosimilar bevacizumab: A provincial experience, PMID: 32727322
Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults, PMID: 32249894
Use of bevacizumab in recurrent glioblastoma, PMID: 25906439
Systemic Bevacizumab (Avastin) for Juvenile-Onset Recurrent Respiratory Papillomatosis: A Systematic Review, PMID: 32959914
Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer, PMID: 29526256
The role of selenium in bevacizumab induced cardiotoxicity, PMID: 30793617
In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer, PMID: 32040774
Microneedle-Mediated Transdermal Delivery of Bevacizumab, PMID: 29996645
Impaired wound healing secondary to bevacizumab, PMID: 31111622
Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia-Related Bleeding and High-Output Cardiac Failure: Significant Inter-Individual Variability in the Need for Maintenance Therapy, PMID: 32753135
[Application of Bevacizumab in Non-small Cell Lung Cancer], PMID: 28442017
Bevacizumab: a new way of doing business. Part 2, PMID: 30482906
Practical management of bevacizumab-related toxicities in glioblastoma, PMID: 25568148
Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality, PMID: 33044752
Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement, PMID: 33405268
Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent, PMID: 26651298
Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma, PMID: 30835573
The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer, PMID: 27138763
The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer, PMID: 27748633
Clinical use of Bevacizumab in treating refractory glaucoma, PMID: 25914729
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice, PMID: 32052341
Gravity influences bevacizumab distribution in an undisturbed balanced salt solution in vitro, PMID: 31584989
Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis, PMID: 31889159
[Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity], PMID: 25459682
Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: A double-masked, randomized trial, PMID: 32502179
For research use only. Not for human or drug use.
